Lymphoma Clinical Trial
Official title:
China Lymphoma Patient Registry Study
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including
Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes
chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With
the progress of treatment, the survival rate of lymphoma patients has been improved. But the
5 year survival rate of lymphoma in China is shorter than that in United States. The reason
is that there is still a gap between China and the United States in disease screening,
diagnosis and treatment.
Observational studies, especially cohort studies, are important tools for understanding
disease progression, treatment, and prognosis in the real world. Observational cohort studies
which involve over 500 patients are currently launched by South Korea and the United States.
China, which has more patients, doesn't have a cohort of patients with lymphoma. So the
primary objective of this study was to establish an observational cohort of patients with
lymphoma in China and follow up the patients for a long period of time to provide basic
support for clinical research and drug development, and continuously improve patient outcomes
and quality of life. The secondary objective is to collect information about diagnosis,
treatment, follow-up and prognosis of lymphoma.
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including
Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes
chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With
the progress of treatment, the survival rate of lymphoma patients has been improved. But the
5 year survival rate of lymphoma in China is shorter than that in United States. The reason
is that there is still a gap between China and the United States in disease screening,
diagnosis and treatment.
Observational studies, especially cohort studies, are important tools for understanding
disease progression, treatment, and prognosis in the real world. Observational cohort studies
which involve over 500 patients are currently launched by South Korea and the United States.
China, which has more patients, doesn't have a cohort of patients with lymphoma. So the
primary objective of this study was to establish an observational cohort of patients with
lymphoma in China and follow up the patients for a long period of time to provide basic
support for clinical research and drug development, and continuously improve patient outcomes
and quality of life. The secondary objective is to collect information about diagnosis,
treatment, follow-up and prognosis of lymphoma.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
| Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
| Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
| Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
| Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |